Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.
Hirva Mamdani(Wayne State University), Edward F. Patz(G1 Therapeutics (United States)), Andrew B. Nixon(Duke University), Scott Antonia(Parker Institute for Cancer Immunotherapy), Guru Sonpavde(AdventHealth Orlando), Michael J. Campa(Duke University), Jeffrey Clarke(Duke Medical Center), Neal Ready(Duke University), JAMES E HERNDON(Duke University), George R. Simon(Ohio Department of Health), Lin Gu(Tsinghua University), Tom Stinchcombe(Duke Medical Center), Jeffrey Crawford(Duke Medical Center)
Cited by 2
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Exploring atomic defects in molybdenum disulphide monolayers
|Nature Communications|2015|1.5k
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|The Lancet Oncology|2016|1.3k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Matching the kinetics of natural enzymes with a single-atom iron nanozyme
|Nature Catalysis|2021|1.1k